Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ANVS
ANVS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ANVS News
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
Jan 16 2026
seekingalpha
Annovis to Conduct 36-Month Extension Study for Further Assessment of Buntanetap in Parkinson's Disease
Dec 19 2025
NASDAQ.COM
Annovis Initiates 36-Month Study for Parkinson's Drug Buntanetap
Dec 18 2025
Newsfilter
Annovis Bio to Host Webinar on Clinical Progress and Future Directions
Dec 16 2025
Newsfilter
Insider Buying Update for Friday, December 12: ANVS, ECL
Dec 12 2025
NASDAQ.COM
Annovis Bio Presents Parkinson's Disease Therapy Data at PSG Annual Meeting
Dec 03 2025
Newsfilter
U.S. Anti-Aging Products Market Driven by Longevity Health Expected to Hit $27 Billion by 2033
Nov 18 2025
Newsfilter
Annovis Bio Shares Surge Following New Data Indicating Buntanetap Prevents Cognitive Decline in Parkinson's Patients
Nov 17 2025
Benzinga
Annovis Completes $6 Million Registered Direct Offering of Common Stock
Oct 15 2025
Yahoo Finance
Annovis Initiates $6 Million Registered Direct Offering
Oct 10 2025
SeekingAlpha
Most Active Stocks in Pre-Market on October 9, 2025: TSLL, IONZ, NVDA, TSLQ, BITF, TTRX, ANVS, BMY, RKT, LAC, PATH, BHP
Oct 09 2025
NASDAQ.COM
Annovis Reveals New Biomarker Findings in Alzheimer's Patients Highlighting Buntanetap's Promise as a Disease-Modifying Therapy
Oct 09 2025
Newsfilter
Canaccord Genuity Reaffirms Buy Rating for Annovis Bio, Keeps $17 Price Target Intact
Sep 30 2025
Benzinga
Annovis Names Mark Guerin as Chief Financial Officer
Sep 25 2025
NASDAQ.COM
Annovis Announces Peer-Reviewed Study on the Pharmacokinetics of Innovative Crystal Buntanetap
Sep 16 2025
Newsfilter
Alphabet Set to Surge by 23%? Check Out 10 Leading Analyst Predictions for Wednesday
Sep 03 2025
Benzinga
Show More News
